Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1801-1820 of 2,120 trials

Rheumatoid Arthritis: CIT-013 Study

We are investigating a new medication, CIT-013, for people with moderately active rheumatoid arthritis. The study aims to see if it helps reduce disease activity and to understand its safety.

Moderately Active Rheumatoid Arthritis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

COVID-19 Vaccine Immunology Study in Finland

We are studying how different COVID-19 vaccines affect immune responses in various groups. This research may help us understand the need for boosters and how well vaccines work against different virus variants.

COVID-196-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Pancreatic Cancer: Hyperpolarized Pyruvate Imaging Study

We are testing a new imaging technique using hyperpolarized pyruvate in patients with pancreatic cancer. This study aims to confirm its safety and gather data to help improve future treatments.

Pancreatic Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Ovarian Cancer: Olaparib and Bevacizumab Study

We are studying how well a new test identifies genetic markers in patients with advanced ovarian cancer and whether combining Olaparib with Bevacizumab improves treatment outcomes. This trial aims to evaluate the safety and effectiveness of this drug combination.

Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Multiple MyelomaEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Recombinant Factor VIIa for Acute Hemorrhagic Stroke

We are studying whether giving a new treatment quickly after a bleeding stroke can improve recovery for patients. This trial focuses on those who have had spontaneous bleeding in the brain and aims to measure their functional outcomes.

Hemorrhagic Stroke>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteHematologyNeurology

CD20-Positive Acute Lymphoblastic Leukemia: Obinutuzumab vs. Rituximab

We are comparing two treatments, obinutuzumab and rituximab, for adults with newly diagnosed CD20-positive acute lymphoblastic leukemia. The goal is to see which treatment helps more patients achieve complete remission safely.

Acute Lymphoblastic Leukemia>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Total Hip Replacement: Tranexamic Acid Injection

We are studying whether injecting Tranexamic acid into the hip joint can reduce blood loss during total hip replacement surgery. This trial compares the effects of TXA with a placebo to see which is more effective.

Hip Osteoarthritis>2 yearsEfficacy phase (II)Standard MedicinesHematologyOrthopedics and Traumatology

Heart Function in Cancer Patients: Nivolumab and Pembrolizumab

We are studying how immunotherapy treatments affect heart function in patients with cancer. This includes monitoring changes in heart performance and rhythm during treatment.

Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyOncology

Improving Ovarian Reserve: rhLH Treatment Study

We are investigating whether a hormone treatment can increase the number of healthy follicles in women trying to conceive. This study aims to assess its effects on fertility and overall safety.

Assisted Fertilization1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Breast Cancer: Palbociclib and Fulvestrant Study

We are investigating if a new treatment combination can help prevent relapse in patients with ER positive HER2 negative breast cancer. This study focuses on those with detectable tumor DNA during treatment.

ER Positive HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Pain After Mastectomy: Comparing Treatments

We are studying the effectiveness of Serratus Plane Block, capsaicin, and botulinum toxin type A for managing chronic neuropathic pain after mastectomy. This trial aims to find out which treatment offers better pain relief for those not helped by standard therapies.

Post-Mastectomy Pain Syndrome>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurologyOncology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Intranasal Lysine-Aspirin for Respiratory Disease

We are studying the effects of a new nasal treatment on asthma and nasal symptoms in patients with NSAID-exacerbated respiratory disease. The goal is to see if it improves breathing and overall quality of life.

Nonsteroidal Anti-Inflammatory Drug Exacerbated Respiratory Disease (N-ERD)1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Chronic Obstructive Pulmonary Disease: Tezepelumab Study

We are investigating whether tezepelumab can help adults with moderate to very severe COPD experience fewer flare-ups and improve their lung function and quality of life compared to a placebo.

Chronic Obstructive Pulmonary Disease (COPD)1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemotePulmonology

Nasopharyngeal Cancer: Nivolumab Treatment Study

We are studying the effectiveness of Nivolumab for patients with nasopharyngeal cancer who have progressed after chemotherapy. We also want to understand how safe this treatment is for these patients.

Nasopharyngeal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Throat and Larynx Cancer: Low-Dose Radiation Therapy

We are studying a new treatment combining low doses of radiation and chemotherapy for patients with advanced throat and larynx cancer. The goal is to see if this approach improves treatment outcomes and is well-tolerated.

Throat and Larynx Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Opioid Use Disorder: Daridorexant Treatment

We are studying whether daridorexant can help reduce illicit substance use in people with opioid use disorder already on buprenorphine. The trial also looks at improvements in cravings, withdrawal symptoms, and overall treatment retention.

Opioid Use Disorder≤3 monthsEfficacy phase (II)11-15 visitsStandard MedicinesPsychiatry